Filing search / Intra-Cellular Therapies, Inc. / "Strategy" / Page 2

PRE 14A

pznod0r7rbu u1nq

19 Apr 21

Preliminary proxy

5:28pm

8-K

EX-99.1

9kj8wz

1 Oct 20

Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer

4:38pm

424B5

m84hz7 jo

11 Sep 20

Prospectus supplement for primary offering

4:44pm

8-K

EX-99.2

xth7qvc0 xs

9 Sep 20

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

5:26pm

424B5

hlz860hri

9 Sep 20

Prospectus supplement for primary offering

4:40pm

8-K

EX-99.1

uqsoqtjkbljcqichx42

23 Mar 20

Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia

7:52am

424B5

vma dzokc

8 Jan 20

Prospectus supplement for primary offering

5:06pm

8-K

EX-99.3

eemr2ges 5v

6 Jan 20

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

4:52pm

8-K

EX-99.2

a3ukit3ldbs 11ro94i

6 Jan 20

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

4:52pm

424B5

epinypri

6 Jan 20

Prospectus supplement for primary offering

4:42pm

S-3ASR

0qobj7ck1q3aq qsdnf

6 Jan 20

Automatic shelf registration

4:02pm

DEFA14A

5b7vf vig5

14 Jun 19

Additional proxy soliciting materials

4:31pm

8-K

EX-99.1

rajp yxri8q6n

8 May 19

Intra-cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update

7:35am